Navigation Links
Nektar to Announce Q1 2008 Financial Results on Wednesday, May 7, 2008, After Close of U.S.-Based Financial Markets
Date:4/30/2008

SAN CARLOS, Calif., April 30 /PRNewswire-FirstCall/ -- Nektar Therapeutics (Nasdaq: NKTR) will announce its financial results for the first quarter ended March 31, 2008 on Wednesday, May 7, 2008, after the close of U.S.-based financial markets. Howard Robin, president and chief executive officer, will host a conference call beginning at 5:00 p.m. Eastern Time (ET).

Investors can access the press release and a live audio-only Webcast of the conference call through a link that is posted on the Investor Relations section of the Nektar website: http://www.nektar.com. The web broadcast of the conference call will be available for replay through Wednesday, May 21, 2008.

To access the conference call, follow these instructions:

Dial: (866) 713-8562 (U.S.); (617) 597-5310 (international)

Passcode: 50572577 (Howard Robin is the host)

An audio replay will also be available shortly following the call through Wednesday, May 21, 2008 and can be accessed by dialing (888) 286-8010 (U.S.); or (617) 801-6888 (international) with a passcode of 73371402.

In the event that any non-GAAP financial measure is discussed on the conference call that is not described in the press release, related information will be made available on the Investor Relations page at the Nektar website as soon as practical after the conclusion of the conference call.

Nektar Therapeutics is a biopharmaceutical company that develops and enables differentiated therapeutics with its industry-leading PEGylation and pulmonary drug development platforms. Nektar's technology and drug development expertise have enabled nine approved products for partners, which include leading biopharmaceuti
'/>"/>

SOURCE Nektar Therapeutics
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Nektar Therapeutics Appoints Tim Harkness as Chief Financial Officer
2. Nektar Therapeutics Appoints Lutz Lingnau as New Board Member
3. Nektar Presents Positive Results from Phase 1 Clinical Trial of NKTR-118 (oral PEG-naloxol) at American College of Clinical Pharmacology Meeting
4. Drs. John Patton of Nektar, Igor Gonda of Aradigm, Tomas Landh of Novo Nordisk, Chris Rhodes of Amylin to Speak at iiBIGs Plenary Panel in Vegas
5. Nektar Therapeutics President and CEO Howard Robin to Present at 2007 BIO InvestorForum
6. Nektar Therapeutics to Present at 2007 BMO Capital Markets Focus on Healthcare Conference
7. Nektar Therapeutics President and CEO Howard W. Robin to Present At JPMorgan 26th Annual Healthcare Conference
8. Nektar Appoints Hoyoung Huh, M.D., Ph.D., to Serve on the Companys Board of Directors
9. Nektar Announces Restructuring to Complete Its Transition to a Therapeutics Drug Development Organization
10. West Concludes Agreement with Nektar
11. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/19/2014)... Charm Sciences is pleased to announce that ... Aflatoxin M1 in raw commingled milk is the first ... The peer reviewed report of the validation by Technology ... and Fisheries Research (ILVO-T&V) has been published by the ... most toxic aflatoxin and a known carcinogen, can be ...
(Date:12/19/2014)... , Dec. 19, 2014 Bina Technologies, Inc. ... announced today that they have been acquired by Roche ... is a privately held company that provides a big ... generation sequencing (NGS) data for the academic and translational ... Sequencing Unit, and will continue to focus on development ...
(Date:12/19/2014)... December 18, 2014 Today, ... its pilot production facility and future company headquarters ... produce innovative new materials that safely and effectively ... only because of its historic, strong support for ... to attract leading edge, technology-based companies such as ...
(Date:12/19/2014)... iLab Solutions, the global leader in ... Bryant as the new Director of Institutional Implementations and ... These two new leadership positions were created to support ... that iLab continues to meet the needs of its ... iLab has been deployed at over 450 core facilities ...
Breaking Biology Technology:Charm Sciences Achieves Independent Validation of First 15 Minute Quantitative Screening Method for Aflatoxin M1 2Bina Technologies is acquired by Roche. 2Bina Technologies is acquired by Roche. 3Technology Company TiFiber™ to Establish Production Facility in Fort Smith, Arkansas with Support from Local Investors 2Technology Company TiFiber™ to Establish Production Facility in Fort Smith, Arkansas with Support from Local Investors 3Technology Company TiFiber™ to Establish Production Facility in Fort Smith, Arkansas with Support from Local Investors 4iLab Solutions Announces Two New Leadership Positions to Meet the Needs of Its Growing Customer Base 2
... Sept. 19 NPS,Pharmaceuticals, Inc. (Nasdaq: NPSP ... Administration,s Office of Orphan Products Development has granted,orphan ... for,injection) for the treatment of hypoparathyroidism, a rare ... FDA-approved therapy. Hypoparathyroidism afflicts approximately 65,000 people ...
... NeurogesX, Inc.,(Nasdaq: NGSX ), a biopharmaceutical company ... it is scheduled to present,at the 2007 UBS Global ... President and Chief Executive Officer, and Jeffery,Tobias, Chief Medical ... September 25, 2007 Time: 9:00 a.m. ...
... Sept. 19 The Pittsburgh Life Sciences,Greenhouse ... life,sciences industry on a fast track for ... in Coventina Healthcare Enterprises, Inc., a medical,device ... Frequency),and multi-modal treatment systems for research, rehabilitation, ...
Cached Biology Technology:PREOS(R) Granted U.S. Orphan Drug Status for Treatment of Hypoparathyroidism 2PREOS(R) Granted U.S. Orphan Drug Status for Treatment of Hypoparathyroidism 3NeurogesX to Present at UBS 2007 Global Life Sciences Conference 2NeurogesX to Present at UBS 2007 Global Life Sciences Conference 3The PLSG Invests $150,000 in Coventina Healthcare Enterprises, Inc., Its Eighth Company Relocation to Pittsburgh 2The PLSG Invests $150,000 in Coventina Healthcare Enterprises, Inc., Its Eighth Company Relocation to Pittsburgh 3
(Date:12/19/2014)...  23andMe, Inc., the leading personal genetics company, today ... differences in genetic ancestry of individuals from across ... immigrants first arrived more than four hundred years ago, ... as a meeting place for peoples from different continents. ... mixing of peoples with African, European, and American origins ...
(Date:12/17/2014)... 16, 2014 Valencell, a leader in performance ... technology to industry leaders such as Intel, Jabra, Atlas, ... biometric wearable products. These products will be showcased at ... Las Vegas . "Our partners ... and robust – with the clinical data to back ...
(Date:12/11/2014)... 09, 2014 Research and Markets ... ( http://www.researchandmarkets.com/research/9ql3kr/biometrics_market ) has announced the addition ... report to their offering. ... the adoption of multimodal biometric systems. Multimodal biometric ... individual for verification and identification purposes. This helps ...
Breaking Biology News(10 mins):23andMe Study Sketches Genetic Portrait of the United States 223andMe Study Sketches Genetic Portrait of the United States 323andMe Study Sketches Genetic Portrait of the United States 4Valencell PerformTek Biometrics Power the Most Accurate Wearables at CES 2015 2Biometrics Market in India 2015-2019: Key Vendors are 3M Cogent, NEC, Safran and Suprema 2
... PITTSBURGH, Jan. 11 A drug that is already ... effective secondary treatment for a rare tumor of the gastrointestinal ... University of Pittsburgh Cancer Institute (UPCI). The findings , ... Jan. 1 issue of Cancer Research . ...
... Rockville, Md., January 11, 2010 New standards to ... key ingredients widely used in infant formulas and a ... in the Food Chemicals Codex (FCC), an internationally recognized ... standards are for three nucleotides, present in breast milk ...
... Baltic Sea, threatening artefacts of the area,s cultural heritage. ... the unfortunate spread is due to climate change, and ... which archaeological remains are at risk. The shipworm is ... only 10 years, and while it has avoided the ...
Cached Biology News:Drug shows promise as new treatment for gut tumor 2Quality and safety of infant formulas, functional foods enhanced by new standards 2Quality and safety of infant formulas, functional foods enhanced by new standards 3Shipworm threatens archaeological treasures 2
Any form, any size, any number of mutageneses. ExonBio provides the best service with double sequecing to make sure the success of the mutagenesis....
Loading Buffer...
Request Info...
Request Info...
Biology Products: